HBW-1020

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameHBW-1020
Drug Alias NameHBW-1020
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitors
TargetsProto-oncogene tyrosine-protein kinase ROSNerve growth factor receptor Trk-AAnaplastic lymphoma kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHyperway Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHyperway Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A